Results 41 to 50 of about 20,787 (190)

Effects of insulin and analogues on carcinogen-induced mammary tumours in high-fat-fed rats

Endocrine Connections, 2018
It is not fully clarified whether insulin glargine, an analogue with a high affinity for insulin-like growth factor-1 receptor (IGF-1R), increases the risk for cancers that abundantly express IGF-1R such as breast cancer or some types of breast cancer ...
Yusaku Mori, Eunhyoung Ko, Rudolf Furrer, Linda C Qu, Stuart C Wiber, I George Fantus, Mario Thevis, Alan Medline, Adria Giacca   +8 more
doaj   +1 more source

Evidence review : liraglutide for the treatment of type 2 diabetes [PDF]

, 2011
This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of liraglutide in the treatment of type 2 diabetes mellitus, based upon the manufacturer’s submission to the National Institute
Cummins, E. (Ewen), HASH(0x5574f4171138), Royle, Pamela, Shyangdan, D. (Deepson), Waugh, Norman   +4 more
core  

Glycemic control and long-acting insulin analog utilization in patients with type 2 diabetes [PDF]

, 2010
Introduction: The objective was to compare glycemic control, insulin utilization, and body weight in patients with type 2 diabetes (T2D) initiated on insulin detemir (IDet) or insulin glargine (IGlar) in a real-life setting in the Netherlands.
A. Dornhorst, A. Patel, A. Philis-Tsimikas, A. Rubino, A.B. King, American Diabetes Association., B.J. Borah, D.M. Nathan, Edith M. Heintjes, Fernie J. A. Penning-van Beest, G. Goodall, G. Rutten, G.E.H.M. Rutten, J.B. Brown, J.B. Marks, K. Hermansen, L. Czupryniak, L. Meneghini, L.F. Meneghini, L.F. Meneghini, M. Monami, M. Yenigun, M.J. Calvert, M.P. Herk-Sukel van, O. Pedersen, O.E. Johansen, P. Fontaine, P. Gaede, P. Hollander, P. Raskin, P. Rossetti, R.M.C. Herings, R.M.C. Herings, R.R. Holman, Ron M. C. Herings, S. Mudaliar, S.A. Brunton, S.E. Nelson, S.I. McFarlane, T. Haak, Torsten E. Christensen, Trine L. Thomsen, UK Prospective Diabetes Study, W. Fakhoury   +43 more
core   +1 more source

Meta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes

ESC Heart Failure, Volume 12, Issue 2, Page 968-979, April 2025.
Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou, Panagiotis Sardellis, Josip Plascevic, Ribeya Awaes‐Mahmood, Justyna Kaczmarek, Daniel Black Boada, Rosa Thuemmler, Sam Philip   +7 more
wiley   +1 more source

New Basal Insulin Toujeo Solostar: Increased Therapeutic Potential for the Control of Dysglycaemia in Diabetes Mellitus

Mìžnarodnij Endokrinologìčnij Žurnal, 2016
This review examines the new formulation of insulin glargine (recombinant) in the form of injections 300 U/ml (Gla‑300, Toujeo®). Gla‑300 is a next generation basal insulin with a novel formulation of insulin glargin delivering the same amount of insulin,
V.V. Poltorak
doaj   +1 more source

The effect of combination therapy of insulin glargine, metformin, and sitagliptin on insulin secretion, insulin resistance, and metabolic parameters in obese subjects with type 2 diabetes [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2016
Introduction. A combination of drugs is required for treatment of obese subjects with diabetes, due to multiple pathogenic mechanisms implicated in the development of both diabetes and obesity. Objective.
Beljić-Živković Teodora, Marjanović-Petković Milica, Vuksanović Miljanka, Soldatović Ivan, Kanlić Dobrila, Topalov Drina   +5 more
doaj   +1 more source

Clinical effectiveness and safety of analogue glargine in type 1 diabetes : systematic review and meta-analysis [PDF]

, 2016
INTRODUCTION: The use of insulin analogues for the treatment of type 1 diabetes mellitus (T1DM) is widespread; however, the therapeutic benefits still require further evaluation given their higher costs.
Acurico, Francisco A., Araujo, Vania E., Diniz, Leonardo M., Godman, Brian, Guerra Júnior, Augusto A., Marra, Lays P., Silva, Thales B. C., Álvares, Juliana   +7 more
core   +1 more source

Efficacy and hypoglycaemia outcomes of once‐weekly insulin icodec versus once‐daily basal insulin comparators across baseline HbA1c, BMI and duration of type 2 diabetes subgroups: A post hoc analysis of ONWARDS 1–5

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This post hoc analysis assessed efficacy and hypoglycaemia outcomes of once‐weekly insulin icodec (icodec) versus once‐daily (OD) basal insulin comparators across different baseline glycated haemoglobin (HbA1c), body mass index (BMI) and type 2 diabetes (T2D) duration subgroups using data from five phase 3a trials of icodec in adults with
Alice Y. Y. Cheng, Gayathri Anil, Luis Canani, Siri Vinther, Ni Wang, Chantal Mathieu   +5 more
wiley   +1 more source

Effectiveness and safety of flexible therapeutic schemes including first- and secondgeneration basal insulins during a pediatric summer diabetes camp

Pediatric Reports, 2020
Outcomes of insulin analogues in pediatric diabetes camps are poorly investigated; no data is available about insulin degludec (IDeg).Our aim was to assess impact of insulin therapy adopted by the participants to a 4-day diabetes camp held in 2017 ...
Stefano Tumini, Laura Comegna, Elisabetta Fioretti, Paola Guidone, Gabriella Levantini, Daniele Panichi, Milena Catenaro, Ilaria Rossi, Flavia Amaro, Giusi Graziano, Maria Chiara Rossi, Paola Cipriano   +11 more
doaj   +1 more source

Insulin therapy DE‐intensificAtion with iGlarLixi: A phase 4, open‐label, parallel‐group randomised controlled trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate the efficacy and safety of transitioning from multiple daily injections (MDIs) insulin regimen to once‐daily, fixed‐ratio combination of basal insulin analog glargine 100 U/mL and a glucagon‐like peptide 1 receptor agonist lixisenatide (iGlarLixi) in people with type 2 diabetes (PwT2D). Materials and Methods Insulin therapy DE‐
Peter Novodvorský, Lenka Thieme, Ivana Laňková, Štěpánka Franková, Alica Veselá, Emil Záhumenský, Tomáš Edelsberger, Marie Löblová, Ondřej Žižka, Miroslav Vytasil, Felipe Lauand, Mireille Bonnemaire, Filip Hrubý, Miloš Mráz, Martin Haluzík   +14 more
wiley   +1 more source